Stock listing
OTC:HEPA Hepion Pharmaceuticals, Inc. Stock
Follow Hepion Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · OTC:HEPA
$0.119 USD +0.023 (+24.6%)
Close on Nov 20, 2026
- Day range
- $0.087 – $0.119 USDNov 20, 2026
- Volume
- 3,803 sharesNov 20, 2026
- Market cap
- $14.63M USDAt the close on Nov 20, 2026 · price × 123.2M shares outstanding
- 52-week range
- $0.034 – $0.220 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3,665 USDMedian day 18,200 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:HEPA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.119 | +0.023 | +24.6% | $0.116 | $0.119 | $0.087 | 3,803 | |
| $0.095 | -0.020 | -17.1% | $0.095 | $0.096 | $0.095 | 15 | |
| $0.115 | 0.000 | 0.0% | $0.115 | $0.115 | $0.115 | 53 | |
| $0.115 | +0.014 | +13.9% | $0.110 | $0.135 | $0.105 | 32,900 | |
| $0.101 | -0.013 | -11.4% | $0.103 | $0.125 | $0.090 | 54,200 | |
| $0.114 | -0.026 | -18.6% | $0.113 | $0.114 | $0.113 | 2,200 | |
| $0.140 | +0.010 | +7.7% | $0.120 | $0.140 | $0.120 | 45,700 | |
| $0.130 | +0.012 | +10.2% | $0.108 | $0.130 | $0.108 | 700 | |
| $0.118 | -0.013 | -9.9% | $0.118 | $0.118 | $0.113 | 13,000 | |
| $0.131 | +0.009 | +7.4% | $0.116 | $0.131 | $0.114 | 2,400 | |
| $0.122 | +0.007 | +6.1% | $0.140 | $0.140 | $0.105 | 69,300 | |
| $0.115 | -0.020 | -14.8% | $0.135 | $0.143 | $0.115 | 166,600 | |
| $0.135 | -0.009 | -6.2% | $0.144 | $0.144 | $0.130 | 98,400 | |
| $0.144 | -0.011 | -7.1% | $0.145 | $0.145 | $0.144 | 700 | |
| $0.155 | -0.025 | -13.9% | $0.179 | $0.179 | $0.155 | 20,300 | |
| $0.180 | +0.040 | +28.6% | $0.190 | $0.210 | $0.162 | 56,300 | |
| $0.140 | -0.010 | -6.7% | $0.135 | $0.220 | $0.135 | 100,500 | |
| $0.150 | +0.012 | +8.7% | $0.134 | $0.150 | $0.120 | 23,700 | |
| $0.138 | +0.007 | +5.3% | $0.131 | $0.138 | $0.131 | 700 | |
| $0.131 | -0.009 | -6.4% | $0.131 | $0.131 | $0.131 | 2,400 | |
| $0.140 | +0.005 | +3.7% | $0.150 | $0.155 | $0.140 | 51,800 | |
| $0.135 | +0.012 | +9.8% | $0.130 | $0.136 | $0.130 | 48,300 | |
| $0.123 | +0.003 | +2.5% | $0.118 | $0.130 | $0.116 | 5,100 | |
| $0.120 | +0.018 | +17.6% | $0.134 | $0.140 | $0.115 | 18,200 | |
| $0.102 | -0.002 | -1.9% | $0.100 | $0.112 | $0.100 | 18,300 | |
| $0.104 | +0.006 | +6.1% | $0.110 | $0.110 | $0.092 | 1,100 | |
| $0.098 | +0.007 | +7.7% | $0.090 | $0.098 | $0.090 | 4,100 | |
| $0.091 | +0.030 | +49.2% | $0.119 | $0.119 | $0.075 | 10,400 | |
| $0.061 | -0.063 | -50.8% | $0.120 | $0.134 | $0.061 | 72,100 | |
| $0.124 | +0.004 | +3.3% | $0.122 | $0.132 | $0.120 | 20,100 | |
| $0.120 | -0.005 | -4.0% | $0.120 | $0.120 | $0.120 | 17,100 | |
| $0.125 | +0.005 | +4.2% | $0.085 | $0.128 | $0.085 | 24,900 | |
| $0.120 | 0.000 | 0.0% | $0.120 | $0.120 | $0.120 | 0 | |
| $0.120 | +0.020 | +20.0% | $0.103 | $0.120 | $0.103 | 21,600 | |
| $0.100 | +0.019 | +23.5% | $0.100 | $0.100 | $0.100 | 200 | |
| $0.081 | -0.019 | -19.0% | $0.095 | $0.098 | $0.081 | 26,500 | |
| $0.100 | -0.014 | -12.3% | $0.120 | $0.120 | $0.095 | 34,800 | |
| $0.114 | +0.004 | +3.6% | $0.100 | $0.114 | $0.100 | 18,200 | |
| $0.110 | +0.030 | +37.5% | $0.075 | $0.123 | $0.075 | 93,700 | |
| $0.080 | -0.007 | -8.0% | $0.080 | $0.080 | $0.080 | 17,900 | |
| $0.087 | +0.011 | +14.5% | $0.079 | $0.104 | $0.049 | 386,400 | |
| $0.076 | +0.013 | +20.6% | $0.076 | $0.076 | $0.076 | 1,100 | |
| $0.063 | -0.016 | -20.3% | $0.066 | $0.075 | $0.059 | 52,600 | |
| $0.079 | -0.001 | -1.3% | $0.074 | $0.079 | $0.074 | 2,200 | |
| $0.080 | +0.003 | +3.9% | $0.063 | $0.080 | $0.063 | 16,500 | |
| $0.077 | +0.005 | +6.9% | $0.077 | $0.077 | $0.077 | 5,100 | |
| $0.072 | +0.003 | +4.3% | $0.067 | $0.081 | $0.067 | 3,900 | |
| $0.069 | -0.010 | -12.7% | $0.063 | $0.069 | $0.063 | 2,700 | |
| $0.079 | 0.000 | 0.0% | $0.079 | $0.079 | $0.079 | 1 | |
| $0.079 | +0.008 | +11.3% | $0.066 | $0.079 | $0.066 | 4,000 | |
| $0.071 | -0.004 | -5.3% | $0.059 | $0.073 | $0.055 | 90,300 | |
| $0.075 | +0.018 | +31.6% | $0.074 | $0.076 | $0.056 | 39,300 | |
| $0.057 | -0.031 | -35.2% | $0.080 | $0.080 | $0.057 | 8,400 | |
| $0.088 | 0.000 | 0.0% | $0.076 | $0.088 | $0.058 | 37,200 | |
| $0.088 | +0.022 | +33.3% | $0.066 | $0.088 | $0.066 | 24,800 | |
| $0.066 | -0.005 | -7.0% | $0.083 | $0.083 | $0.066 | 21,600 | |
| $0.071 | -0.004 | -5.3% | $0.080 | $0.080 | $0.064 | 17,300 | |
| $0.075 | -0.005 | -6.3% | $0.088 | $0.090 | $0.075 | 44,100 | |
| $0.080 | -0.015 | -15.8% | $0.075 | $0.090 | $0.075 | 41,100 | |
| $0.095 | +0.042 | +79.2% | $0.054 | $0.095 | $0.053 | 271,500 | |
| $0.053 | -0.012 | -18.5% | $0.064 | $0.064 | $0.053 | 7,800 | |
| $0.065 | -0.009 | -12.2% | $0.075 | $0.075 | $0.054 | 7,800 | |
| $0.074 | +0.013 | +21.3% | $0.052 | $0.074 | $0.052 | 19,200 | |
| $0.061 | -0.014 | -18.7% | $0.065 | $0.065 | $0.061 | 71,300 | |
| $0.075 | 0.000 | 0.0% | $0.071 | $0.075 | $0.071 | 6,800 | |
| $0.075 | 0.000 | 0.0% | $0.075 | $0.075 | $0.075 | 26 |
Splits
4 splits since 2018 · OTC:HEPA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-50 | Consolidation | |
| 1-for-20 | Consolidation | |
| 1-for-70 | Consolidation | |
| 1-for-8 | Consolidation |
- Ticker
- OTC:HEPA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news
Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest
Oct 26, 2026
Closed $0.131 (-6.4%) on Oct 26, 2026
Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
Oct 19, 2026
Closed $0.102 (-1.9%) on Oct 19, 2026
Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
Oct 14, 2026
Closed $0.091 (+49.2%) on Oct 14, 2026
Hepion Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 3 in the last 12 months · 3 in all · newest Oct 26, 2026 · oldest 2026
- Decks
- 42 decks · latest Jul 22, 2024
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $10.37M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- -1.02
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Hepion Pharmaceuticals, Inc. · OTC:HEPA | US$14.63M | US$10.37M | n/a | n/a | n/a | n/a | n/a | n/a | -1.02 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Celularity Inc. · NASDAQ:CELU | US$15.02M | US$50.46M | n/a | 2.7× | n/a | n/a | −117.3% | n/a | 1.47 |
| Context Therapeutics Inc. · NASDAQ:CNTX | US$14.70M | −US$19.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 0.99 |
| NewcelX Ltd. · NASDAQ:NCEL | US$14.67M | US$14.35M | n/a | n/a | n/a | 2.4× | n/a | 0.1× | 0.89 |
| Vectorite Biomedical, Inc. · TPEX:4170 | US$14.21M | US$9.17M | 4.9× | 4.9× | n/a | 0.9× | 156.6% | 0.0× | n/a |
| Estrella Immunopharma, Inc. · NASDAQ:ESLA | US$14.11M | US$14.01M | n/a | n/a | n/a | n/a | n/a | n/a | 1.31 |
| Citius Pharmaceuticals, Inc. · NASDAQ:CTXR | US$13.96M | −US$3.05M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.71 |
| TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549 | US$13.69M | US$11.86M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| Actuate Therapeutics, Inc. · NASDAQ:ACTU | US$13.60M | US$11.50M | n/a | n/a | n/a | n/a | n/a | n/a | 1.75 |
| BeyondSpring, Inc. · NASDAQ:BYSI | US$13.57M | US$12.99M | 0.3× | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Median of the others | US$14.16M | US$11.68M | 2.6× | 3.8× | 0.9× | 19.6% | 0.0× | 1.31 |
Team and board
Officers
| Officer | Role |
|---|---|
| Sireesh Appajosyula | Chief Executive Officer and Director |
| Gary Stetz | Chief Financial Officer and Director |
| Chase LoPriore | VP, Corporate Development & Director |
| Bobbi Fox-Caminiti | Director of Operations |
| Vincent LoPriore | Executive Chairman and Director |
Board
| Director | Role |
|---|---|
| Michael Purcell | Independent Director & Audit Chair |
| Vincent LoPriore | Executive Chairman and Director |
| Chase LoPriore | VP, Corporate Development & Director |
| Danina Fisher | Independent Director |
| Gary Stetz | Chief Financial Officer and Director |
| James Gordon Liddy | Independent Director |
| Sireesh Appajosyula | Chief Executive Officer and Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Aug 14, 2025 | |
| Q1 2025 | Apr 8, 2025 | +10.9% |
| Q4 2024 | Feb 26, 2025 | −7.4% |
| Q3 2024 | Nov 18, 2024 · Before open | +1.1% |
| Q2 2024 | Aug 13, 2024 · After close | +11.8% |
| Q1 2024 | Apr 16, 2024 · After close | +4.4% |
| Q4 2023 | Jan 6, 2024 · Before open | +13.1% |
| Q3 2023 | Nov 20, 2023 · After close | −1.3% |
| Q2 2023 | Aug 14, 2023 · After close | +1.4% |
| Q1 2023 | May 12, 2023 · After close | +1.8% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2022 | Mar 1, 2023 | −9.1% |
| Q3 2022 | Nov 14, 2022 · After close | +9.9% |
| Q2 2022 | Aug 15, 2022 · After close | −1.5% |
| Q1 2022 | May 16, 2022 · After close | −4.2% |
| Q4 2021 | Mar 2, 2022 | −0.8% |
| Quarter to Sep 30, 2021 | Nov 15, 2021 · After close | −3.4% |
| Quarter to Jun 30, 2021 | Aug 16, 2021 · After close | −0.7% |
| Quarter to Mar 31, 2021 | May 14, 2021 · After close | +6.9% |
| Quarter to Dec 31, 2020 | Mar 31, 2021 · After close | +8.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (July 2024) | Merger or acquisition | 28 slides | Jul 22, 2024 |
| Investor Presentation (October 2023) | Investor deck | 36 slides | October 2023 |
| Investor Presentation (August 2023) | Investor deck | 38 slides | August 2023 |
| Investor Presentation (July 2023) | Investor deck | 38 slides | Jul 24, 2023 |
| Investor Presentation (July 2023) | Investor deck | 38 slides | July 2023 |
| Investor Presentation (May 2023) | Investor deck | 37 slides | May 2023 |
| Investor Presentation (April 2023) | Investor deck | 38 slides | April 2023 |
| Investor Presentation (February 2023) | Investor deck | 39 slides | February 2023 |
| Investor Presentation (November 2022) | Investor deck | 34 slides | November 2022 |
| Investor Presentation (November 2022) | Investor deck | 34 slides | November 2022 |
All 42 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | ||||||
| Research and development | 445.5K | 11.8M | 35.6M | 33.3M | 20.4M | 12.0M | 3.18M | 7.59M | 13.4M | 13.7M |
| Operating income | -4.16M | -19.3M | -48.4M | -45.5M | -30.4M | -20.1M | -7.77M | -14.6M | -20.6M | -21.0M |
| Depreciation and amortization | 30.8K | 67.1K | 77.5K | 86.1K | 34.5K | 26.7K | 18.8K | 28.0K | ||
| EBITDA | -19.3M | -48.4M | -45.4M | -30.3M | -20.1M | -7.74M | -14.6M | -21.0M | ||
| Interest expense | 9.46K | 10.2K | 8.86K | 31.2K | 555.0K | 339.2K | ||||
| Income before tax | -8.28M | -16.2M | -49.3M | -45.1M | -32.7M | -20.3M | -7.95M | -9.99M | -15.0M | -16.8M |
| Income tax | -2.97M | -409.0K | -2.88M | 0 | 30.6K | -908.7K | -536.0K | -1.95M | -1.91M | |
| Net income | -8.28M | -13.2M | -48.9M | -42.2M | -32.7M | -20.4M | -7.04M | -9.45M | -13.1M | -14.9M |
| Earnings per share, basic | -0.88 | -107.35 | -616.07 | -11.90 | -0.47 | -2.10 | -5.95 | -97.35 | -1.34 | -2.04 |
| Earnings per share, diluted | -0.88 | -107.35 | -616.07 | -11.90 | -0.47 | -2.10 | -6.11 | -1.39 | -2.41 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.83M | 406.4K | 14.8M | 51.2M | 91.3M | 40.7M | 13.9M | 2.83M | 5.95M | 13.0M |
| Current assets | 3.07M | 1.61M | 17.5M | 56.5M | 97.5M | 42.6M | 14.4M | 2.97M | 6.06M | 13.2M |
| Property, plant and equipment | 29.5K | 81.6K | 152.8K | 108.4K | 57.2K | 32.4K | 56.6K | 67.6K | ||
| Goodwill | 0 | 1.87M | 1.87M | 1.87M | 1.87M | 1.87M | 1.87M | |||
| Total assets | 3.07M | 1.61M | 18.1M | 60.2M | 103.6M | 48.6M | 20.6M | 8.19M | 11.3M | 18.4M |
| Accounts payable | 167.8K | 220.2K | 2.35M | 2.67M | 2.45M | 3.72M | 491.6K | 748.4K | 1.56M | 1.63M |
| Current liabilities | 299.4K | 3.14M | 5.29M | 7.89M | 8.21M | 4.66M | 1.61M | 2.85M | 2.60M | 2.94M |
| Total debt | 0 | |||||||||
| Total liabilities | 402.4K | 3.48M | 10.8M | 10.4M | 10.6M | 8.12M | 4.99M | 6.21M | 7.55M | 9.33M |
| Shareholders' equity | 2.67M | -1.86M | 7.28M | 49.9M | 93.0M | 40.5M | 15.6M | 1.72M | 3.70M | 9.06M |
| Shares outstanding | 11.6M | 139.2K | 96.4K | 3.81M | 76.2M | 32.0M | 3.76M | 247.0K | 9.79M | 75.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3.27M | -18.2M | -40.9M | -35.0M | -31.2M | -16.2M | -7.57M | -15.6M | -19.2M |
| Capital spending | -14.3K | -16.3K | -130.4K | -88.0K | -51.5K | -14.7K | |||
| Free cash flow | -40.9M | -35.0M | -31.4M | -16.3M | -7.62M | -19.2M | |||
| Cash from investing | -132.1K | -600.0K | -14.3K | -14.1K | -130.4K | -85.8K | -51.5K | 900 | -14.7K |
| Cash from financing | 4.83M | 4.35M | 4.49M | -5.14M | 82.0M | 43.1M | 18.7M | 12.5M | 24.8M |
| Change in cash | 1.42M | -14.4M | -36.4M | -40.2M | 50.6M | 26.8M | 11.1M | -3.12M | 5.58M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q/A · Quarterly report, amended | Nov 17, 2026 | Quarterly report | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D · Big-stake notice | Oct 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 21, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 21, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Oct 14, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 9, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 2, 2026 | Current report | SEC |
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 16, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| DEF 14C | Sep 10, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2026 | Material contract | SEC |
| PRE 14C | Aug 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 27, 2026 | Material contract | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2026 | Management or board change | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 20, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 7, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2026 | Offer document | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| D | Aug 5, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 4, 2026 | Material contract | SEC |
| 3 · Initial statement of ownership | Jul 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| 3 · Initial statement of ownership | May 26, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| SCHEDULE 13D · Big-stake notice | May 1, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| D | Apr 22, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 22, 2026 | Material contract | SEC |
| 8-K · Current report | Apr 14, 2026 | Material contract | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 18, 2026 | Management or board change | SEC |
| 10-K · Annual report | Mar 11, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 15, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 25-NSE | Jul 22, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 30, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 12, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 9, 2025 | Management or board change | SEC |
| 8-K · Current report | May 30, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | May 19, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| NT 10-Q · Late filing notice | May 15, 2025 | Explanation request | SEC |
| 8-K · Current report | May 12, 2025 | Current report | SEC |
| 8-K · Current report | May 6, 2025 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Apr 24, 2025 | Other filings | SEC |
| PRER14A | Apr 23, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 17, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Apr 8, 2025 | Annual report | SEC |
| 8-K/A · Current report, amended | Apr 4, 2025 | Current report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2025 | Explanation request | SEC |
| 8-K · Current report | Mar 20, 2025 | Current report | SEC |
| 8-K · Current report | Mar 19, 2025 | Current report | SEC |
| 8-K · Current report | Mar 10, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Feb 7, 2025 | Meeting notice | SEC |
| ARS/A · Annual report to shareholders, amended | Feb 7, 2025 | Annual report | SEC |
| ARS · Annual report to shareholders | Feb 7, 2025 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | Jan 27, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 27, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 24, 2025 | Big-stake notice | SEC |
| 424B4 · Prospectus | Jan 23, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 22, 2025 | Other filings | SEC |
| S-1MEF · Registration of more shares for the same offering | Jan 21, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 17, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 17, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 15, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 15, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Jan 14, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 14, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 14, 2025 | Offer document | SEC |
| 10-K/A · Annual report, amended | Jan 13, 2025 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Jan 2, 2025 | Other filings | SEC |
| S-1 · Registration statement | Dec 26, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | Dec 5, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Dec 2, 2024 | Meeting notice | SEC |
| 425 | Nov 21, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 21, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 425 | Sep 5, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 5, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 425 | Aug 7, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 7, 2024 | Management or board change | SEC |
| D | Jul 23, 2024 | Other filings | SEC |
| 425 | Jul 22, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 22, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jul 16, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jul 15, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 12, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 12, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jul 11, 2024 | Offer document | SEC |
| 10-K/A · Annual report, amended | Jun 24, 2024 | Annual report | SEC |
| 10-Q · Quarterly report | May 21, 2024 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 15, 2024 | Explanation request | SEC |
| 10-K · Annual report | Apr 16, 2024 | Annual report | SEC |
| NT 10-K · Late filing notice | Apr 1, 2024 | Explanation request | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 6, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 6, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 20, 2024 | Management or board change | SEC |
| 8-K · Current report | Feb 16, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 7, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 3, 2024 | Current report | SEC |
| 8-K · Current report | Dec 7, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 28, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 20, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2023 | Explanation request | SEC |
| EFFECT · Notice that a registration is effective | Nov 9, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 6, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 3, 2023 | Other filings | SEC |
| S-1 · Registration statement | Oct 31, 2023 | Offer document | SEC |
| D | Oct 3, 2023 | Other filings | SEC |
| 8-K · Current report | Oct 2, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Oct 2, 2023 | Offer document | SEC |
| 4 · Change in ownership | Sep 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 6, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jul 24, 2023 | Current report | SEC |
| 8-K · Current report | Jul 21, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Jul 21, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jul 14, 2023 | Offer document | SEC |
| 8-K · Current report | Jun 22, 2023 | Meeting outcome | SEC |
| 8-K · Current report | May 22, 2023 | Current report | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2023 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Apr 10, 2023 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2023 | Explanation request | SEC |
| 8-K · Current report | Dec 15, 2022 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Nov 21, 2022 | Meeting notice | SEC |
| D | Nov 15, 2022 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | Nov 9, 2022 | Meeting notice | SEC |
| 8-K · Current report | Nov 8, 2022 | Material contract | SEC |
| 8-K · Current report | Oct 17, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Aug 15, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2022 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jul 26, 2022 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jul 22, 2022 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Jul 20, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 5, 2022 | Insider trade | SEC |
This page holds 200 of 725 filings. Open Filings
Cap table
Built by 6ix from Hepion Pharmaceuticals, Inc.’s releases
- Common shares
- 123,220,476
- Fully diluted
- 123,220,476
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 123,220,476 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 123,220,476 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Tamar D Howson Other companies: Immunic, Inc. (Director · Since at least Oct 11, 2019); Cue Biopharma, Inc. (Director · Sep 17, 2020 – Jan 3, 2023 · Past); Lite Strategy, Inc. (Director · Jul 1, 2019 – Sep 29, 2023 · Past); VivoSim Labs, Inc. (Director · Jun 5, 2013 – Jul 26, 2018 · Past); Warner Chilcott PLC (Director · May 7, 2013 – Sep 30, 2013 · Past); Aradigm Corporation (Director · Nov 3, 2010 – May 25, 2012 · Past); Soligenix, Inc. (Director · Sep 23, 2010 – Jun 22, 2011 · Past); Oncotelic Therapeutics Inc (Director · Apr 2, 2010 – May 28, 2015 · Past); Idenix Pharmaceuticals Inc (Director · Mar 30, 2010 – Aug 5, 2014 · Past); Lexicon Pharmaceuticals, Inc. (EVP of Bus Dev · Apr 2, 2007 – Feb 7, 2008 · Past); Bristol-Myers Squibb Company (SVP, Corp & Bus Development · Mar 7, 2006 – Dec 1, 2006 · Past) | Director · Dec 14, 2016 – Apr 10, 2017 · Past |
| James Sapirstein Other companies: INmune Bio Inc. (Director · Since at least Sep 8, 2026); Cocrystal Pharma, Inc. (Chief Executive Officer · Since at least Jun 3, 2026); ZyVersa Therapeutics, Inc. (Chairman and CEO – 8 Prime Biosciences · Since at least Jan 5, 2023); Onconetix, Inc. (Director · Feb 23, 2022 – Sep 26, 2024 · Past); Blue Water Acquisition Corp (Director · Dec 15, 2020 – Dec 15, 2020 · Past); Marizyme, Inc. (Interim CEO, Director · Sep 10, 2020 – Mar 5, 2021 · Past); GridAI Technologies Corp. (Chairman and CEO, Director · Oct 8, 2019 – Jul 2, 2024 · Past); Lunai Bioworks Inc. (Director · Mar 6, 2018 – Jun 25, 2024 · Past); ProBility Media Corp. (Director · Nov 8, 2016 – Feb 15, 2017 · Past); RespireRx Pharmaceuticals Inc (Director · Mar 31, 2016 – Dec 9, 2017 · Past) | Chief Executive Officer, Director · Mar 19, 2014 – Jan 3, 2018 · Past |
| John Brancaccio Other companies: Tiziana Life Sciences Ltd (Non-Executive Director · Since at least Nov 5, 2026); OKYO Pharma Limited (Director · Since at least May 16, 2022); Accustem Sciences Inc (Board Member · Since at least Dec 1, 2021); Cardiff Oncology, Inc. (Director · Jan 23, 2012 – Mar 9, 2022 · Past); Synergy Pharmaceuticals Inc (Director · Aug 3, 2011 – Jul 4, 2018 · Past); Callisto Pharmaceuticals Inc (Director · Dec 18, 2008 – Jan 17, 2013 · Past) | Chairman, Director · Oct 7, 2013 – Feb 19, 2024 · Past |
| Gary Jacob Other companies: OKYO Pharma Limited (Chief Development Officer/Director · Since at least May 16, 2022); Virpax Pharmaceuticals, Inc. (Director · Feb 16, 2021 – Jan 1, 2022 · Past); Callisto Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 17, 2013 – Jan 17, 2013 · Past); Cardiff Oncology, Inc. (Director · Jan 23, 2012 – Mar 23, 2021 · Past); Synergy Pharmaceuticals Inc (Executive Chairman, Director · Dec 6, 2011 – Jun 15, 2018 · Past) | Director · Oct 7, 2013 – Feb 19, 2024 · Past |
| Bernard Denoyer Other companies: OKYO Pharma Limited (Non-Executive Director · Since at least May 16, 2022); Callisto Pharmaceuticals Inc (Senior Vice President, Finance · Jan 17, 2013 – Jan 17, 2013 · Past); Synergy Pharmaceuticals Inc (Senior Vice President, Finance · Aug 3, 2011 – Jun 24, 2016 · Past) | Chief Financial Officer · Oct 7, 2013 – Apr 3, 2014 · Past |
| Christopher McGuigan Other companies: Cardiff Oncology, Inc. (Director · Jan 14, 2013 – Feb 14, 2013 · Past); Synergy Pharmaceuticals Inc (Director · Aug 3, 2011 – Jul 24, 2015 · Past); Inhibitex Inc (Director · Sep 19, 2007 – Feb 13, 2012 · Past) | Director · Oct 7, 2013 – Dec 3, 2014 · Past |
| Michael Purcell Other companies: International Money Express, Inc. (Director · Since at least Jul 26, 2018); Tabula Rasa HealthCare Inc (Director · Jul 18, 2018 – Nov 3, 2023 · Past); Patriot National Inc (Director · Jan 1, 2017 – Jan 4, 2017 · Past) | Independent Director & Audit Chair · Since at least Mar 5, 2024 |
| Gary Stetz Other companies: Canton Strategic Holdings, Inc. (Independent Director · Since at least Apr 28, 2025); BCB Bancorp, Inc. (nj) (Director · Oct 14, 2011 – Mar 14, 2018 · Past) | Chief Financial Officer and Director · Since at least Mar 16, 2026 |
| Thomas Phd Adams Other companies: Cardiff Oncology, Inc. (Executive Chairman, Director · Jan 4, 2016 – Jun 17, 2020 · Past); Synergy Pharmaceuticals Inc (Director · Jul 24, 2015 – Jul 3, 2018 · Past) | Director · Sep 20, 2016 – May 18, 2021 · Past |
| Arnold Lippa Other companies: RespireRx Pharmaceuticals Inc (Exec. Chairman & CSO, Director · Jan 29, 2016 – Sep 30, 2020 · Past) | Director · Nov 30, 2015 – May 18, 2021 · Past |
All 25 people
| Person | Seat |
|---|---|
| James Gordon Liddy Other companies: Canton Strategic Holdings, Inc. (Director · Since at least Jun 11, 2025) | Director · Since at least Aug 19, 2026 |
| John T Cavan Other companies: Aegerion Pharmaceuticals Inc (VP & Chief Accounting Officer · Oct 21, 2010 – Oct 21, 2010 · Past) | Chief Financial Officer · Apr 1, 2016 – May 18, 2021 · Past |
| Peter Wijngaard Other companies: The Medicines Company (Chief Development Officer · May 30, 2019 – Jan 6, 2020 · Past) | Director · Jun 10, 2020 – Nov 24, 2023 · Past |
| Robert T Foster Other companies: Aurinia Pharmaceuticals Inc (Director · Sep 21, 2023 – Sep 21, 2023 · Past) | CEO and Director, Director · Jun 10, 2016 – Sep 18, 2023 · Past |
| Sireesh Appajosyula Other companies: Canton Strategic Holdings, Inc. (CEO · Since at least Jan 11, 2022) | Chief Executive Officer and Director · Since at least Mar 16, 2026 |
| Vincent LoPriore Other companies: Canton Strategic Holdings, Inc. (Director · Since at least Apr 9, 2025) | Executive Chairman and Director · Since at least Mar 16, 2026 |
| William Karl Hornung Other companies: CervoMed Inc. (Chief Financial Officer · Sep 21, 2018 – Jan 27, 2022 · Past) | Chief Financial Officer · Jun 23, 2014 – Jun 4, 2015 · Past |
| Anand Reddi | Director · Jun 27, 2022 – Jun 27, 2022 · Past |
| Bobbi Fox-Caminiti | Director of Operations · Since at least Nov 5, 2026 |
| Chase LoPriore | VP, Corporate Development & Director · Since at least Mar 16, 2026 |
| Danina Fisher | Independent Director · Since at least Jul 1, 2026 |
| Gary S Stetz II | Director · Since at least Jul 1, 2026 |
| John Z Sullivan-Bolyai | Chief Medical Officer · Mar 2, 2016 – Jul 6, 2017 · Past |
| Kaouthar Lbiati | Director · Jun 27, 2022 – Feb 19, 2024 · Past |
| Timothy M Block | Director · Nov 26, 2013 – Feb 19, 2024 · Past |
Log in to ask 6ix AI your own questions about Hepion Pharmaceuticals, Inc.